SCHEMBL4036255

SCHEMBL4036255

CC(=O)c1ccc(-c2ccccc2Cl)o1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.73
MEN1 O00255 2/20 0.73
KMT2A Q03164 2/20 0.73
NPSR1 Q6W5P4 1/20 0.73
RAB9A P51151 6/20 0.63
TDP1 Q9NUW8 1/20 0.63
MAPT P10636 3/20 0.61
LMNA P02545 2/20 0.61
CASP3 P42574 2/20 0.61
SMN1; SMN2 Q16637 2/20 0.61
SENP7 Q9BQF6 2/20 0.61
SLC9A1 P19634 1/20 0.61
MAPK1 P28482 1/20 0.61
RECQL P46063 1/20 0.61
NPC1 O15118 3/20 0.60
ERCC5 P28715 1/20 0.60
FEN1 P39748 1/20 0.60
S1PR4 O95977 1/20 0.58
SENP6 Q9GZR1 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14267945 0.87 SLC9A1 (0.63) ALDH1A1MEN1KMT2ANPSR1RAB9A
SCHEMBL28269605 0.84 ALDH1A1 (0.75) ALDH1A1MEN1KMT2ANPSR1RAB9A
SCHEMBL29352723 0.84 ALDH1A1 (1.00) ALDH1A1MEN1KMT2ANPSR1RAB9A
SCHEMBL4987351 0.84 ALDH1A1 (1.00) ALDH1A1MEN1KMT2ANPSR1RAB9A
SCHEMBL4942886 0.83 ALDH1A1 (0.69) ALDH1A1MEN1KMT2ANPSR1RAB9A
SCHEMBL10028045 0.82 RAB9A (0.69) ALDH1A1MEN1KMT2ANPSR1RAB9A
SCHEMBL13078669 0.80 SLC9A1 (0.63) ALDH1A1MEN1KMT2ANPSR1TDP1
SCHEMBL21067946 0.79 RAB9A (0.69) ALDH1A1MEN1KMT2ANPSR1RAB9A
SCHEMBL18862264 0.78 RAB9A (0.81) ALDH1A1MEN1KMT2ANPSR1RAB9A
SCHEMBL30175841 0.77 ALDH1A1 (0.54) ALDH1A1MEN1KMT2ANPSR1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120010259-A1 Methods of Treating an Overweight or Obese Subject ZAFGEN, INC. 2012-01-12 US disclosed
EP-1501509-A4 ARYL-LINK-ARYL SUBSTITUTED THIAZOLIDINE-DIONE AND OXAZOLIDINE-DIONE AS SODIUM CHANNEL BLOCKERS MERCK & CO INC (US) 2009-07-15 EP disclosed
US-7348348-B2 Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers MERCK & CO. INC. (US) 2008-03-25 US disclosed
US-20050165072-A1 Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers MERCK SHARP & DOHME CORP. 2005-07-28 US disclosed
EP-1501509-A2 ARYL-LINK-ARYL SUBSTITUTED THIAZOLIDINE-DIONE AND OXAZOLIDINE-DIONE AS SODIUM CHANNEL BLOCKERS Merck & Co., Inc. (US) 2005-02-02 EP disclosed
WO-2004024061-A2 ARYL-LINK-ARYL SUBSTITUTED THIAZOLIDINE-DIONE AND OXAZOLIDINE-DIONE AS SODIUM CHANNEL BLOCKERS MERCK & CO., INC. (US) 2004-03-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050165072-A1 Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers KCNN1, KCNH1, KCNN2 ALDH1A1 993/4885MEN1 2070/4885KMT2A 1874/4885
US-20120010259-A1 Methods of Treating an Overweight or Obese Subject METAP2, METAP1, ACER2 ALDH1A1 802/4885MEN1 1530/4885KMT2A 444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.